NSD2 and cancer: While BRD4 and MEK inhibitors show redundancy in their responses through cancer-acquired super-enhancers, NSD2 inhibition affects the expression of a different subset of RAS-target genes embedded in large H3K36me2 regions and complements the effects of MEK or BRD4 inhibitors to reach a more comprehensive inhibition of oncogenic RAS-driven transcriptional programs.